Introduction
breast cancer
DISEASE, BREAST CANCER
Hormone receptor (HR)-positive breast cancer represents the largest subtype of the disease, accounting for over 80% of cases in the United Kingdom (UK) [Palbociclib (Ibrance®) is a CDK4/6i that was shown to be effective in HR-positive/HER2-negative locally advanced or MBC in the pivotal PALOMA clinical trials [